LGND Earnings

LGND reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 58.16M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.63 by 0%. The stock experienced a 2.5% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following LGND's earnings announcement on 2026-02-26, the stock price moved by 2.5% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, LGND's stock price tends to shift by an average of -4.31% in the 10 days leading up to earnings and 1.46% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate LGND's annual revenue to reach 60.08M, while the EPS is projected at 1.40. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.66% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LGND's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.66%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LGND's stock price typically moves by -4.31% in the 10 days before its earnings and 1.46% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.40 and revenue of 60.08M.

The earnings call indicates strong financial performance, with raised guidance and record high revenues. Product development shows momentum with potential blockbuster drugs and a robust pipeline. Market strategy is solid with royalty revenue growth and strategic investments. Financial health is stable with manageable expenses and significant cash reserves. Shareholder returns are likely supported by positive financial outcomes. Q&A insights reinforce optimistic guidance and strategic focus. Given the market cap, the stock price is expected to react positively, likely increasing by 2% to 8% over the next two weeks.